Rainmed MedicalHKSE:02297 49 EBITDA Margin % is -452.30% as of Dec. 2025. GuruFocus rates HKSE:02297 with a GF Score™ of 49/100 and a GF Value™ of HK$0.08 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Rainmed Medical ranks worse than 90.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rainmed Medical's EBITDA for the
six
months ended in Dec. 2025 was HK$-43.83 Mil. Rainmed Medical's Revenue for the
six
months ended in Dec. 2025 was HK$9.69 Mil. Therefore, Rainmed Medical's EBITDA margin for the quarter that ended in Dec. 2025 was -452.30%.
Rainmed Medical (HKSE:02297) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rainmed Medical EBITDA Margin % Related Terms
Rainmed Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rainmed Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02297 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Rainmed Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rainmed Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rainmed Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rainmed Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rainmed Medical (HKSE:02297) has a EBITDA Margin % of -452.30% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rainmed Medical and its competitors. According to the industry distribution chart, Rainmed Medical ranks #737 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 90.4%.
Is Rainmed Medical's EBITDA Margin % too high?
Rainmed Medical's current EBITDA Margin % is -452.30%. Based on the distribution chart, Rainmed Medical ranks #737 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Rainmed Medical has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Rainmed Medical ranks #737 out of 815 companies for EBITDA Margin %. This places Rainmed Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rainmed Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rainmed Medical's current EBITDA Margin % is -452.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.22 — trading 175% above its estimated fair value. The current EBITDA Margin % is -452.30%. Rainmed Medical's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current EBITDA Margin % is -452.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rainmed Medical (HKSE:02297) Overvalued in 2026?
Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued.
The current stock price of HK$0.22 is trading 175% above its estimated GF Value™ of HK$0.08.
GuruFocus considers Rainmed Medical to be Significantly Overvalued.
Key valuation signals for HKSE:02297:
EBITDA Margin %: -452.30%
GF Value™: HK$0.08 vs. price of HK$0.22 (175% above fair value)
No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
49GF Score
Get the complete analysis for HKSE:02297
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02297 has been successfully added to your 
